Home > Publications Database > Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms. > print

001     280223
005     20250824001744.0
024 7 _ |a 10.3389/fneur.2025.1593042
|2 doi
024 7 _ |a pmid:40757033
|2 pmid
024 7 _ |a pmc:PMC12316182
|2 pmc
024 7 _ |a altmetric:177718692
|2 altmetric
037 _ _ |a DZNE-2025-00901
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a van de Burgt, Nikita A
|b 0
245 _ _ |a Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms.
260 _ _ |a Lausanne
|c 2025
|b Frontiers Research Foundation
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754634141_29798
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The presence of autoantibodies against myelin oligodendrocyte glycoprotein (MOG) is a hallmark of MOG antibody-associated disease (MOGAD), a recently defined demyelinating disease entity presenting with core clinical features of optic neuritis, myelitis, and acute disseminated encephalomyelitis. Although MOG antibodies have also been described in a small number of patients with other conditions, including mental disorders, their prevalence and clinical specificity in patients with isolated psychotic symptoms remain unclear. Here, we screened sera from 262 patients with at least one psychotic episode and 166 control subjects for the presence of MOG antibodies of the immunoglobulin G (IgG) isotype with a live cell-based assay. Serum reactivity to additional antigens was assessed by immunohistochemistry. Four patients, representing 1.5% of the patient cohort, and one control individual, representing. 0.6% of the healthy control cohort, were seropositive for MOG-IgG antibodies. Of the four MOG-IgG seropositive patients, three experienced visual hallucinations. Overall, MOG antibodies were detected at a low frequency in patients with psychotic episodes. While we cannot exclude the possibility of false-positive results or seroconversion due to secondary myelin damage, the association with visual hallucinations in three out of four MOG-IgG seropositive patients may point toward an underlying autoimmune etiology.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a autoantibodies
|2 Other
650 _ 7 |a mental disorders
|2 Other
650 _ 7 |a myelin oligodendrocyte glycoprotein antibody-associated disease
|2 Other
650 _ 7 |a neuroinflammation
|2 Other
650 _ 7 |a psychiatry
|2 Other
650 _ 7 |a psychosis
|2 Other
700 1 _ |a Kulsvehagen, Laila
|b 1
700 1 _ |a Mané-Damas, Marina
|b 2
700 1 _ |a Lutz, Luc
|b 3
700 1 _ |a Lecourt, Anne-Catherine
|b 4
700 1 _ |a Monserrat, Clara
|b 5
700 1 _ |a Vinke, Anita M
|b 6
700 1 _ |a Küçükali, Cem I
|b 7
700 1 _ |a Zong, Shenghua
|b 8
700 1 _ |a Hoffmann, Carolin
|b 9
700 1 _ |a González-Vioque, Emiliano
|b 10
700 1 _ |a Arango, Celso
|b 11
700 1 _ |a Leibold, Nicole K
|b 12
700 1 _ |a Losen, Mario
|b 13
700 1 _ |a Molenaar, Peter C
|b 14
700 1 _ |a Tüzün, Erdem
|b 15
700 1 _ |a van Beveren, Nico J M
|b 16
700 1 _ |a Mané, Anna
|b 17
700 1 _ |a Rouhl, Rob P W
|b 18
700 1 _ |a van Amelsvoort, Therese A M J
|b 19
700 1 _ |a Risk, for Genetic
|b 20
700 1 _ |a Psychosis, Outcome of
|b 21
|e Collaboration Author
700 1 _ |a Pröbstel, Anne-Katrin
|0 P:(DE-2719)9003515
|b 22
|e Last author
|u dzne
700 1 _ |a Martinez-Martinez, Pilar
|b 23
773 _ _ |a 10.3389/fneur.2025.1593042
|g Vol. 16, p. 1593042
|0 PERI:(DE-600)2564214-5
|p 1593042
|t Frontiers in neurology
|v 16
|y 2025
|x 1664-2295
856 4 _ |u https://pub.dzne.de/record/280223/files/DZNE-2025-00901.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/280223/files/DZNE-2025-00901.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280223
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 22
|6 P:(DE-2719)9003515
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT NEUROL : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-11T07:34:54Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-11T07:34:54Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-01-11T07:34:54Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1013045
|k AG Pröbstel
|l Clinical Neurology and Neuroimmunology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013045
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21